克罗恩病：初诊
Crohn's disease: the first visit.
作者信息
Di Palma Jack A, Farraye Francis A
机构信息
Dr. Di Palma is a Professor of Medicine and Director of the Division of Gastroenterology at the University of South Alabama College of Medicine in Mobile, Alabama.
出版信息
Gastroenterol Hepatol (N Y). 2011 Mar;7(3):163-9.
Abstract
A Crohn's disease patient's first visit to a new practice is the optimal time to collect important clinical data and identify appropriate therapies. A methodologic approach to this visit is crucial. The focus of this visit should be on preparing the patient for the initiation of treatment, with particular attention to the necessary steps prior to the use of immunosuppressive and biologic agents. This paper is intended to provide recommendations and a checklist for the initial assessment and evaluation of patients with Crohn's disease.
摘要
克罗恩病患者首次就诊新诊所是收集重要临床数据并确定合适治疗方法的最佳时机。对此就诊采用一种方法学途径至关重要。此次就诊的重点应是让患者为开始治疗做好准备，尤其要关注使用免疫抑制和生物制剂之前的必要步骤。本文旨在为克罗恩病患者的初始评估和评价提供建议及清单。
相似文献
1
Crohn's disease: the first visit.克罗恩病：初诊
Gastroenterol Hepatol (N Y). 2011 Mar;7(3):163-9.
2
Crohn's disease: the subsequent visit.克罗恩病：后续随访
Gastroenterol Hepatol (N Y). 2013 Jan;9(1):16-20.
3
Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study.克罗恩病回结肠切除术后并发症的危险因素，主要关注术前免疫抑制和生物治疗的影响：一项回顾性国际多中心研究。
United European Gastroenterol J. 2016 Dec;4(6):784-793. doi: 10.1177/2050640615600116. Epub 2015 Aug 6.
4
Anoperineal lesions in Crohn's disease: French recommendations for clinical practice.克罗恩病的肛门直肠病变：法国临床实践推荐。
Tech Coloproctol. 2017 Sep;21(9):683-691. doi: 10.1007/s10151-017-1684-y. Epub 2017 Sep 19.
5
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.通过RAND方法评估炎症性肠病中免疫抑制药物的适用性：意大利炎症性肠病研究小组（IG-IBD）立场声明
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
6
[Anti-TNF therapy in treatment of luminal Crohn's disease].[抗TNF治疗在腔内型克罗恩病治疗中的应用]
Acta Med Croatica. 2013 Apr;67(2):179-89.
7
Optimising monitoring in the management of Crohn's disease: a physician's perspective.优化克罗恩病管理中的监测：医生的视角。
J Crohns Colitis. 2013 Sep;7(8):653-69. doi: 10.1016/j.crohns.2013.02.005. Epub 2013 Apr 4.
8
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients.西班牙克罗恩病和溃疡性结肠炎工作组（GETECCU）以及克罗恩病和溃疡性结肠炎患者协会（ACCU）关于炎症性肠病患者心理问题管理的建议。
Gastroenterol Hepatol. 2018 Feb;41(2):118-127. doi: 10.1016/j.gastrohep.2017.10.003. Epub 2017 Dec 21.
9
Natalizumab for induction of remission in Crohn's disease.那他珠单抗用于诱导克罗恩病缓解
Cochrane Database Syst Rev. 2006 Jul 19(3):CD006097. doi: 10.1002/14651858.CD006097.
10
Natalizumab for induction of remission in Crohn's disease.那他珠单抗用于诱导克罗恩病缓解
Cochrane Database Syst Rev. 2007 Jan 24(1):CD006097. doi: 10.1002/14651858.CD006097.pub2.
引用本文的文献
1
Culture-based characterization of gut microbiota in inflammatory bowel disease.基于培养的炎症性肠病肠道微生物群特征分析
Front Microbiol. 2025 Feb 20;16:1538620. doi: 10.3389/fmicb.2025.1538620. eCollection 2025.
2
Phylogenetic and pathotype analysis of stool isolates from Egyptian patients with inflammatory bowel disease.对埃及炎症性肠病患者粪便分离株的系统发育和致病型分析。
Germs. 2019 Dec 2;9(4):172-181. doi: 10.18683/germs.2019.1173. eCollection 2019 Dec.
3
Vaccinating Patients With Inflammatory Bowel Disease.为炎症性肠病患者接种疫苗
Gastroenterol Hepatol (N Y). 2016 Sep;12(9):540-546.
4
5
Health maintenance and inflammatory bowel disease.健康维护与炎症性肠病
Curr Gastroenterol Rep. 2014 Oct;16(10):402. doi: 10.1007/s11894-014-0402-4.
6
Crohn's disease: the subsequent visit.克罗恩病：后续随访
Gastroenterol Hepatol (N Y). 2013 Jan;9(1):16-20.
本文引用的文献
1
Optimising use of thiopurines in inflammatory bowel disease.优化硫唑嘌呤在炎症性肠病中的应用
Frontline Gastroenterol. 2010 Apr;1(1):44-51. doi: 10.1136/fg.2009.000174. Epub 2010 Apr 1.
2
Serologic Markers in the Diagnosis and Management of IBD.炎症性肠病诊断与管理中的血清学标志物
Gastroenterol Hepatol (N Y). 2007 Jun;3(6):424-6.
3
Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge.为炎症性肠病患者接种疫苗：消化内科医生知识的不足。
Inflamm Bowel Dis. 2011 Dec;17(12):2536-40. doi: 10.1002/ibd.21667. Epub 2011 Apr 28.
4
Emerging prognostic markers to determine Crohn's disease natural history and improve management strategies: a review of recent literature.用于确定克罗恩病自然病史并改善管理策略的新兴预后标志物：近期文献综述
Gastroenterol Hepatol (N Y). 2010 Feb;6(2):99-107.
5
Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.炎症性肠病病程预测的血清学和实验室标志物。
World J Gastroenterol. 2010 Jun 7;16(21):2604-8. doi: 10.3748/wjg.v16.i21.2604.
6
A practical guide to vaccinating the inflammatory bowel disease patient.炎症性肠病患者的接种实用指南。
Am J Gastroenterol. 2010 Jun;105(6):1231-8. doi: 10.1038/ajg.2009.733. Epub 2010 Jan 26.
7
Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity.评估克罗恩病严重程度时，克罗恩病活动度和 Harvey-Bradshaw 指数之间的相关性。
Clin Gastroenterol Hepatol. 2010 Apr;8(4):357-63. doi: 10.1016/j.cgh.2010.01.001. Epub 2010 Jan 21.
8
Recommended adult immunization schedule: United States, 2010.2010年美国成人免疫接种推荐时间表
Ann Intern Med. 2010 Jan 5;152(1):36-9. doi: 10.7326/0003-4819-152-1-201001050-00008.
9
Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.粪便钙卫蛋白与克罗恩病简单内镜评分（SES-CD）的相关性比 CRP、血白细胞和 CDAI 更密切。
Am J Gastroenterol. 2010 Jan;105(1):162-9. doi: 10.1038/ajg.2009.545. Epub 2009 Sep 15.
10
Biological therapies for inflammatory bowel diseases.炎症性肠病的生物疗法
Gastroenterology. 2009 Apr;136(4):1182-97. doi: 10.1053/j.gastro.2009.02.001. Epub 2009 Feb 26.
Zotero 插件